Quick Takeaways: Why It Matters? This deal gives Merck Animal Health an early, exclusive window into a gene-therapy pipeline for chronic and age-related diseases in pets, while Rejuvenate Bio secures non-dilutive R&D support and a $6M financing round to advance its platform...
Quick Takeaways: Why It Matters? Genflow’s early canine SIRT6 data are strong enough that big animal‑health players now want a closer look, but not yet strong enough for anyone to sign a deal. The expanded web of NDAs suggests real strategic interest ...
